In preclinical studies, CFT8919 as monotherapy showed activity in EGFR L858R‐driven NSCLC models both in vitro and in vivo, and importantly remained effective in models carrying secondary resistance mutations (like EGFR T790M and C797S) [380], suggesting CFT8919 may be effective in patients with resistance due to EGFR secondary mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.